Ranibizumab 0.5 mg
Sponsors
Novartis, Genentech, Inc., Novartis Pharmaceuticals, Alcon Research, Aswan University
Conditions
Age Related Macular DegenerationAge-Related Macular DegenerationAge-related Macular DegenerationAge-related Macular Degeneration (AMD)Central Retinal Vein OcclusionChoroidal Neovascularization, Age-related Macular DegenerationDiabetic Macular EdemaDiabetic Retinopathy
Phase 1
ESBA1008 Safety, Tolerability and Effects in Wet Age-Related Macular Degeneration (AMD) Patients
CompletedNCT01304693
Start: 2010-10-31End: 2013-03-31Updated: 2014-07-17
Safety Tolerability and Efficacy of Intravitreal LMG324 in the Treatment of Neovascular Age-Related Macular Degeneration
TerminatedNCT02398500
Start: 2015-07-22End: 2016-05-20Updated: 2019-06-05
Phase 2
Safety and Efficacy of Ranibizumab in Diabetic Macular Edema With Center Involvement
CompletedNCT00284050
Start: 2005-10-31End: 2008-06-30Updated: 2011-02-24
Multicenter 12 Months Clinical Study to Evaluate Efficacy and Safety of Ranibizumab Alone or in Combination With Laser Photocoagulation vs. Laser Photocoagulation Alone in Proliferative Diabetic Retinopathy (PRIDE)
CompletedNCT01594281
Start: 2012-12-11End: 2017-12-05Updated: 2019-03-15
Phase 3
Evaluation of Safety and Efficacy of Once Monthly Ranibizumab Injections in Chinese Patients With Wet Age Related Macular Degeneration (AMD) Patients
CompletedNCT00826371
Start: 2009-01-31Updated: 2016-11-18
Safety and Efficacy of Ranibizumab in Diabetic Macular Edema
TerminatedNCT01131585
Start: 2010-06-30End: 2011-07-31Updated: 2012-08-30
Efficacy and Safety of Ranibizumab 0.5 vs Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia
CompletedNCT01922102
Start: 2013-09-11End: 2016-09-14Updated: 2019-06-24
Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Branch Retinal Vein Occlusion (BRVO)
CompletedNCT01976338
Start: 2013-11-12End: 2016-03-28Updated: 2017-05-08
Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Central Retinal Vein Occlusion (CRVO)
CompletedNCT01976312
Start: 2013-11-12End: 2016-03-14Updated: 2017-05-30
Phase 4
Comparison of Safety, Effectiveness and Quality of Life Outcomes Between Labeled Versus Treat and Extend Regimen in Turkish Patients With Choroidal Neovascularisation Due to Age-related Macular Degeneration (AMD)
CompletedNCT01148511
Start: 2010-02-28End: 2012-04-30Updated: 2013-05-30
A Comparison of Ranibizumab and Aflibercept for the Development of Geographic Atrophy in (Wet) AMD Patients
CompletedNCT02130024
Start: 2014-04-11End: 2017-11-15Updated: 2019-06-05
Systemic Vascular Endothelial Growth Factor (VEGF) Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Neovascular Age-related Macular Degeneration
CompletedNCT02257632
Start: 2015-04-08End: 2017-06-08Updated: 2019-05-07
Study of Efficacy of Ranibizumab in Different Regimens in Patients With Diabetic Macula Edema
CompletedNCT02366468
Start: 2015-02-23End: 2017-06-08Updated: 2019-01-04
Unknown Phase
An Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Subjects With Choroidal Neovascularization Secondary to AMD or Macular Edema Secondary to RVO
CompletedNCT00379795
Start: 2005-04-30End: 2008-09-30Updated: 2017-05-11
An Extension Study to Evaluate Safety and Tolerability of Ranibizumab in Macular Edema Secondary to Retinal Vein Occlusion (Cohort 2)
CompletedNCT01442064
Start: 2008-07-31End: 2010-07-31Updated: 2012-01-10
Laser Photocoagulation and Ranibizumab Treatment in Proliferative Diabetic Retinopathy
CompletedNCT07819253
Start: 2023-07-01End: 2025-07-31Updated: 2026-09-15